{"cursor":"37282","size":15,"audio":[],"currentlang":"en","article":"{{Drugbox\n| Verifiedfields = changed verifiedrevid = 458283255 image =\n\n\n| type = mab mab_type = mab source = zu/o target = alpha-4 integrin\n\n\n| tradename = Tysabri Drugs.com = MedlinePlus = a605006 licence_EU = Natalizumab\n| licence_US = Natalizumab pregnancy_AU = C pregnancy_US = C legal_status = Rx-\n| only routes_of_administration = Intravenous infusion\n\n\n| bioavailability = n/a protein_bound = metabolism = elimination_half-life = 11\n| Â± 4 days\n\n\n| CAS_number_Ref = CAS_number = 189261-10-7 ATC_prefix = L04 ATC_suffix = AA23\n| ATC_supplemental = PubChem = DrugBank_Ref = DrugBank = DB00108 UNII_Ref =\n| UNII = 3JB47N2Q2P ChEMBL_Ref = ChEMBL = 1201607 ChemSpiderID_Ref =\n| ChemSpiderID = NA\n\n\n| chemical_formula = molecular_weight = 149 kDa\n}} 'Natalizumab' is a humanized monoclonal antibody against the cell adhesion\nmolecule Î±4-integrin. Natalizumab is used in the treatment of multiple sclerosis\nand Crohn's disease. It is co-marketed by Biogen Idec and Ãlan as 'Tysabri', and\nwas previously named 'Antegren'. Natalizumab is administered by intravenous\ninfusion every 28 days. The drug is believed to work by reducing the ability of\ninflammatory immune cells to attach to and pass through the cell layers lining\nthe intestines and bloodâbrain barrier. Natalizumab has proven effective in\ntreating the symptoms of both diseases, preventing relapse, vision loss,\ncognitive decline and significantly improving quality of life in people with\nmultiple sclerosis, as well as increasing rates of remission and preventing\nrelapse in Crohn's disease.\n\nNatalizumab was approved in 2004 by the U.S. Food and Drug Administration (FDA).\nIt was subsequently withdrawn from the market by its manufacturer after it was\nlinked with three cases of the rare neurological condition progressive\nmultifocal leukoencephalopathy (PML) when administered in combination with\ninterferon beta-1a, another immunosuppressive drug often used in the treatment\nof multiple sclerosis. After a review of safety information and no further\ndeaths, the drug was returned to the US market in 2006 under a special\nprescription program. As of June 2009, ten cases of PML were known. However, twenty-\nfour cases of PML had been reported since its reintroduction by October 2009,\nshowing a sharp rise in the number of fatalities and prompting a review of the\nchemical for human use by the European Medicines\nAgency. By January 2010, 31 cases\nof PML were attributed to natalizumab. The FDA did\nnot withdraw the drug from the market because its clinical benefits outweigh the\nrisks involved. In the European Union, it has been approved for human\nuse only for the treatment of multiple sclerosis and only then as a monotherapy\nbecause the initial cases of PML, and later the fatalities, were said by the\nmanufacturers to be linked to the use of previous medicines by the patients.\n\nBiogen Idec announced the initiation of the first clinical trial of natalizumab\nas a potential cancer treatment as of September 5, 2008.\n","linknr":948,"url":"Tysabri","recorded":1376420244,"links":["/w/index.php?title=Natalizumab&action=edit","/w/index.php?title=Natalizumab&action=edit","//bits.wikimedia.org/favicon/wikipedia.ico","/w/opensearch_desc.php","//en.wikipedia.org/w/api.php?action=rsd","//creativecommons.org/licenses/by-sa/3.0/","/w/index.php?title=Special:RecentChanges&feed=atom","http://en.wikipedia.org/wiki/Natalizumab","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmw.PopUpMediaTransform%7Cskins.vector&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.visualEditor.viewPageTarget.noscript&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=startup&only=scripts&skin=vector&*","//bits.wikimedia.org/geoiplookup","//meta.wikimedia.org","/w/index.php?title=Tysabri&redirect=no","#mw-navigation","#p-search","/wiki/Nomenclature_of_monoclonal_antibodies","/wiki/Monoclonal_antibody#Applications","/wiki/File:Engineered_monoclonal_antibodies.svg","/wiki/Monoclonal_antibody#Production","/wiki/Humanized","/wiki/Mouse","/wiki/Antigen","/wiki/Integrin","/wiki/Trade_name","/wiki/American_Society_of_Health-System_Pharmacists","/wiki/Drugs.com","http://www.drugs.com/monograph/natalizumab.html","/wiki/MedlinePlus","http://www.nlm.nih.gov/medlineplus/druginfo/meds/a605006.html","/wiki/Regulation_of_therapeutic_goods","/wiki/European_Medicines_Agency","http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/epar_search.jsp&murl=menus/medicines/medicines.jsp&searchkwByEnter=true&status=Authorised&keyword=Natalizumab&searchType=Name&jsenabled=true","/wiki/U.S._Food_and_Drug_Administration","http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Natalizumab&SearchType=BasicSearch","/wiki/Pregnancy_category","/wiki/Australia","/wiki/United_States","/wiki/Regulation_of_therapeutic_goods","/wiki/Route_of_administration","/wiki/Intravenous_infusion","/wiki/Bioavailability","/wiki/Biological_half-life","/wiki/CAS_registry_number","http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=189261-10-7&rn=1","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/Anatomical_Therapeutic_Chemical_Classification_System","/wiki/ATC_code_L04","http://www.whocc.no/atc_ddd_index/?code=L04AA23","/wiki/DrugBank","http://www.drugbank.ca/drugs/DB00108","/wiki/Unique_Ingredient_Identifier","http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=3JB47N2Q2P","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","/wiki/ChEMBL","https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201607","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","/wiki/Chemical_formula","/wiki/Molecular_mass","/wiki/Atomic_mass_unit","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","/wiki/Wikipedia:WikiProject_Chemicals/Chembox_validation","//en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458283255&page2=Natalizumab","/wiki/Humanized_antibody","/wiki/Monoclonal_antibody","/wiki/Cell_adhesion_molecule","/wiki/Integrin","/wiki/Multiple_sclerosis","/wiki/Crohn%27s_disease","/wiki/Biogen_Idec","/wiki/%C3%89lan","/wiki/Intravenous_therapy","/wiki/Inflammation","/wiki/Immune_system","/wiki/Intestine","/wiki/Blood%E2%80%93brain_barrier","/wiki/Quality_of_life","/wiki/Food_and_Drug_Administration_(United_States)","/wiki/List_of_withdrawn_drugs","/wiki/Progressive_multifocal_leukoencephalopathy","/wiki/Interferon_beta-1a","/wiki/Immunosuppressive_drug","/wiki/European_Medicines_Agency","#cite_note-1","#cite_note-2","#cite_note-June2009-3","#cite_note-Medscape-4","#cite_note-5","/wiki/European_Union","#cite_note-6","#Indications","#Multiple_sclerosis","#Crohn.27s_disease","#Adverse_effects","#Mechanism_of_action","#In_multiple_sclerosis","#In_Crohn.27s_disease","#Interactions","#Legal_status","#References","#External_links","/w/index.php?title=Natalizumab&action=edit&section=1","/w/index.php?title=Natalizumab&veaction=edit&section=1","/wiki/Multiple_sclerosis","/wiki/Crohn%27s_disease","#cite_note-7","#cite_note-PREU-8","#cite_note-9","/w/index.php?title=Natalizumab&action=edit&section=2","/w/index.php?title=Natalizumab&veaction=edit&section=2","/wiki/Multiple_sclerosis","/wiki/Treatment_of_multiple_sclerosis","/wiki/Expanded_Disability_Status_Scale","/wiki/Placebo","#cite_note-Polman-10","#cite_note-Polman-10","#cite_note-EU-11","/wiki/Interferon_beta-1a","#cite_note-pmid18354844-12","#cite_note-13","#cite_note-Galetta-14","#cite_note-15","#cite_note-16","#cite_note-17","/wiki/Corticosteroid","#cite_note-18","/wiki/Lesion","#cite_note-Polman-10","#cite_note-19","/wiki/Antibody","#cite_note-pmid18354844-12","#cite_note-pmid18360634-20","#cite_note-21","/wiki/Infusion","#cite_note-pmid18354844-12","/wiki/Monotherapy","#cite_note-EU-11","#cite_note-pmid18354844-12","/w/index.php?title=Natalizumab&action=edit&section=3","/w/index.php?title=Natalizumab&veaction=edit&section=3","/wiki/Crohn%27s_disease","/wiki/Randomized_controlled_trial","/wiki/Remission_(medicine)","#cite_note-pmid12510039-22","#cite_note-23","/wiki/Crohn%27s_disease","/wiki/Tumor_necrosis_factor-alpha","/wiki/Infliximab","#cite_note-24","#cite_note-Sands-25","#cite_note-Hyams-26","#cite_note-27","#cite_note-28","/w/index.php?title=Natalizumab&action=edit&section=4","/w/index.php?title=Natalizumab&veaction=edit&section=4","/wiki/Progressive_multifocal_leukoencephalopathy","/wiki/JC_virus","/wiki/Immunocompromised","#cite_note-BloombergDec152008-29","#cite_note-pmid15947080-30","#cite_note-FDAAug2008-31","#cite_note-BloombergDec152008-29","/wiki/Package_insert","#cite_note-32","#cite_note-.22pmid21777829.22-33","#cite_note-.22pmid21777829.22-33","/wiki/Prevalence","#cite_note-.22pmid21777829.22-33","#cite_note-.22pmid21777829.22-33","/wiki/Postmarketing_surveillance","/wiki/Liver","/wiki/Jaundice","#cite_note-FDA_Safety_Alerts_for_Drugs-34","#cite_note-EMEA_press_release-35","#cite_note-Q.26A-36","#cite_note-titleMultiple_Sclerosis_-_Natalizumab_.28Tysabri.29_Can_Rarely_Cause_Liver_Problems-37","/wiki/Hepatotoxicity","/wiki/Bilirubin","/wiki/Elevated_transaminases","#cite_note-DHP-38","/wiki/Challenge-dechallenge-rechallenge","#cite_note-DHP-38","/wiki/Liver_function_tests","/wiki/Sequela","/wiki/Liver_transplantation","/wiki/Death","#cite_note-DHP-38","/wiki/Fatigue_(medical)","/wiki/Allergy","/wiki/Anaphylaxis","#cite_note-pmid17876741-39","/wiki/Headache","/wiki/Nausea","/wiki/Common_cold","#cite_note-Sands-25","/wiki/Fever","#cite_note-Hyams-26","/wiki/Contraindication","#Interactions","/wiki/Melanoma","#cite_note-40","#cite_note-pmid18389881-41","/wiki/Infection","/wiki/Cancer","#cite_note-pmid18354844-12","/w/index.php?title=Natalizumab&action=edit&section=5","/w/index.php?title=Natalizumab&veaction=edit&section=5","/wiki/File:AntibodyChains.svg","//upload.wikimedia.org/wikipedia/commons/thumb/b/bb/AntibodyChains.svg/200px-AntibodyChains.svg.png","/wiki/File:AntibodyChains.svg","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/magnify-clip.png","/wiki/Antibody","/wiki/Humanized_antibody","/wiki/Monoclonal_antibodies","/wiki/Integrin","/wiki/White_blood_cell","/wiki/Organ_(anatomy)","/wiki/Mechanism_of_action","#cite_note-Rice2005-42","/w/index.php?title=Natalizumab&action=edit&section=6","/w/index.php?title=Natalizumab&veaction=edit&section=6","/wiki/Multiple_sclerosis_signs_and_symptoms","/wiki/Lesion","/wiki/Inflammation","/wiki/T-lymphocyte","/wiki/Blood%E2%80%93brain_barrier","/wiki/Endothelium","/wiki/Central_nervous_system","/wiki/VLA-4","/wiki/VCAM-1","/wiki/Parenchyma","/wiki/Osteopontin","/wiki/Leukocyte","#cite_note-Tysabri_label-43","/wiki/CD34","#cite_note-pmid18235044-44","/w/index.php?title=Natalizumab&action=edit&section=7","/w/index.php?title=Natalizumab&veaction=edit&section=7","/wiki/Addressin","/wiki/Venules","/wiki/Lymphatic_system","/wiki/Peyer%27s_patches","/wiki/Animal_model","/wiki/Irritable_bowel_syndrome","#cite_note-Tysabri_label-43","/w/index.php?title=Natalizumab&action=edit&section=8","/w/index.php?title=Natalizumab&veaction=edit&section=8","/wiki/Progressive_multifocal_leukoencephalopathy","/wiki/Opportunistic_infection","/wiki/JC_virus","/wiki/Interferon_beta-1a","/wiki/Sequela","#cite_note-nejm-pml1-45","#cite_note-nejm-pml2-46","/wiki/Astrocytoma","#cite_note-Van_Assche-47","/wiki/Azathioprine","/wiki/Corticosteroid","/wiki/Infliximab","#cite_note-Van_Assche-47","#cite_note-Yousry-48","#cite_note-pmid17136224-49","#cite_note-pmid17521672-50","#cite_note-pmid17122725-51","/wiki/Contraindication","/wiki/Immunosuppression","#cite_note-Tysabri_label-43","#cite_note-Tysabri_label-43","#cite_note-June2009-3","#cite_note-WSJ08-52","/wiki/United_States_Food_and_Drug_Administration","#cite_note-Medscape-4","/wiki/Black_box_warning","#cite_note-Tysabri_label-43","/wiki/Corticosteroid","#cite_note-Tysabri_label-43","#cite_note-pmid18360634-20","#cite_note-pmid17136224-49","#cite_note-pmid17434098-53","#cite_note-pmid18360634-20","/w/index.php?title=Natalizumab&action=edit&section=9","/w/index.php?title=Natalizumab&veaction=edit&section=9","/wiki/Multiple_sclerosis","/wiki/FDA_Fast_Track_Development_Program","/wiki/Clinical_trial","#cite_note-NYT-54","/wiki/First-line_treatment","#cite_note-55","#cite_note-56","#cite_note-NYT-54","/wiki/Alosetron","/wiki/Committee_for_Medicinal_Products_for_Human_Use","/wiki/European_Medicines_Agency","#cite_note-PREU-8","/wiki/Health_Canada","/wiki/Prescription_drug","/wiki/Physician","#cite_note-57","/w/index.php?title=Natalizumab&action=edit&section=10","/w/index.php?title=Natalizumab&veaction=edit&section=10","#cite_ref-1","http://www.emea.europa.eu/pdfs/human/press/pr/67119009en.pdf","/wiki/European_Medicines_Agency","#cite_ref-2","http://www.reuters.com/article/companyNewsAndPR/idUSLT39797520091029","/wiki/Reuters","#cite_ref-June2009_3-0","#cite_ref-June2009_3-1","http://www.reuters.com/article/idUSTRE55S39X20090629","/wiki/Reuters","#cite_ref-Medscape_4-0","#cite_ref-Medscape_4-1","http://www.medscape.com/viewarticle/716536","/wiki/Medscape","#cite_ref-5","http://www.webmd.com/multiple-sclerosis/news/20080801/ms-drug-tysabri-tied-to-brain-infection","/wiki/WebMD","#cite_ref-6","http://www.boston.com/business/ticker/2008/09/biogen_idec_tes.html","/wiki/The_Boston_Globe","#cite_ref-7","http://www.fiercepharma.com/story/tysabri-safety-falls-under-emea-scrutiny/2009-10-26","#cite_ref-PREU_8-0","#cite_ref-PREU_8-1","http://www.emea.europa.eu/pdfs/human/press/pr/15260806en.pdf","/wiki/European_Medicines_Agency","#cite_ref-9","/wiki/Digital_object_identifier","http://dx.doi.org/10.1111%2Fj.1365-2141.2011.08794.x","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/21749361","/wiki/Help:CS1_errors#displayauthors","//en.wikipedia.org/w/index.php?title=Template:Cite_pmid/21749361&action=edit&editintro=Template:Cite_pmid/editintro2","#cite_ref-Polman_10-0","#cite_ref-Polman_10-1","#cite_ref-Polman_10-2","/wiki/N._Engl._J._Med.","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa044397","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/16510744","#cite_ref-EU_11-0","#cite_ref-EU_11-1","http://www.emea.europa.eu/humandocs/PDFs/EPAR/tysabri/H-603-PI-en.pdf","/wiki/European_Medicines_Agency","#cite_ref-pmid18354844_12-0","#cite_ref-pmid18354844_12-1","#cite_ref-pmid18354844_12-2","#cite_ref-pmid18354844_12-3","#cite_ref-pmid18354844_12-4","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18354844","#cite_ref-13","http://www.neurology.org/content/68/16/1299.abstract","/wiki/Digital_object_identifier","http://dx.doi.org/10.1212%2F01.wnl.0000259521.14704.a8","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17438220","#cite_ref-Galetta_14-0","http://www.abstracts2view.com/aan2008chicago/view.php?nu=AAN08L_P02.156","http://web.archive.org/web/20071029041416/http://www.elan.com/news/full.asp?ID=1061738","/wiki/%C3%89lan","http://www.elan.com/news/full.asp?ID=1061738","#cite_ref-15","/wiki/Digital_object_identifier","http://dx.doi.org/10.2165%2F00023210-200822100-00004","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18788835","#cite_ref-16","/wiki/Digital_object_identifier","http://dx.doi.org/10.1002%2Fana.21163","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17696126","#cite_ref-17","http://www.pslgroup.com/dg/265832.htm","#cite_ref-18","http://www.webwire.com/ViewPressRel.asp?aId=21727","#cite_ref-19","/wiki/Digital_object_identifier","http://dx.doi.org/10.1212%2F01.wnl.0000260064.77700.fd","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17452584","#cite_ref-pmid18360634_20-0","#cite_ref-pmid18360634_20-1","#cite_ref-pmid18360634_20-2","http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936307","/wiki/Digital_object_identifier","http://dx.doi.org/10.2147%2Ftcrm.2007.3.2.259","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1936307","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18360634","#cite_ref-21","/wiki/Digital_object_identifier","http://dx.doi.org/10.1212%2F01.wnl.0000277457.17420.b5","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17761550","#cite_ref-pmid12510039_22-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa020732","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/12510039","#cite_ref-23","/wiki/Digital_object_identifier","http://dx.doi.org/10.1111%2Fj.1572-0241.2007.01508.x","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18042106","#cite_ref-24","/wiki/Digital_object_identifier","http://dx.doi.org/10.1159%2F000111023","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18239400","#cite_ref-Sands_25-0","#cite_ref-Sands_25-1","/wiki/Digital_object_identifier","http://dx.doi.org/10.1002%2Fibd.20014","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17206633","#cite_ref-Hyams_26-0","#cite_ref-Hyams_26-1","http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00005176-200702000-00006","/wiki/Digital_object_identifier","http://dx.doi.org/10.1097%2F01.mpg.0000252191.05170.e7","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17255829","#cite_ref-27","http://www.fda.gov/bbs/topics/NEWS/2008/NEW01775.html","/wiki/Food_and_Drug_Administration","#cite_ref-28","http://www.emea.europa.eu/humandocs/PDFs/EPAR/natalizumab/H-624-RAR-en.pdf","/wiki/European_Medicines_Agency","http://www.emea.europa.eu/pdfs/human/opinion/Natalizumab_Q&A_53096407en.pdf","#cite_ref-BloombergDec152008_29-0","#cite_ref-BloombergDec152008_29-1","http://www.bloomberg.com/apps/news?pid=20601087&sid=ahUhAZaAQqgs&refer=home","#cite_ref-pmid15947080_30-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa051586","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15947080","#cite_ref-FDAAug2008_31-0","http://www.fda.gov/cder/drug/InfoSheets/HCP/natalizumab2008HCP.htm","/wiki/Wikipedia:Link_rot","#cite_ref-32","http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm","/wiki/United_States_Food_and_Drug_Administration","#cite_ref-.22pmid21777829.22_33-0","#cite_ref-.22pmid21777829.22_33-1","#cite_ref-.22pmid21777829.22_33-2","#cite_ref-.22pmid21777829.22_33-3","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2FS1474-4422%2811%2970149-1","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/21777829","#cite_ref-FDA_Safety_Alerts_for_Drugs_34-0","http://www.fda.gov/medwatch/safety/2008/safety08.htm#Tysabri","/wiki/Food_and_Drug_Administration","#cite_ref-EMEA_press_release_35-0","http://emea.europa.eu/humandocs/PDFs/EPAR/tysabri/PR_Tysabri_13948908en.pdf","/wiki/European_Medicines_Agency","/wiki/Wikipedia:Link_rot","#cite_ref-Q.26A_36-0","http://emea.europa.eu/humandocs/PDFs/EPAR/tysabri/Q&A_Tysabri_14590808en.pdf","/wiki/European_Medicines_Agency","/wiki/Wikipedia:Link_rot","http://www.nelm.nhs.uk/Record%20Viewing/vR.aspx?id=591422","http://www.medscape.com/viewarticle/570796","#cite_ref-titleMultiple_Sclerosis_-_Natalizumab_.28Tysabri.29_Can_Rarely_Cause_Liver_Problems_37-0","http://www.healthcentral.com/multiple-sclerosis/c/6639/21073/liver/","#cite_ref-DHP_38-0","#cite_ref-DHP_38-1","#cite_ref-DHP_38-2","http://www.fda.gov/medwatch/safety/2008/Tysabri_dhcp_letter.pdf","/wiki/Biogen_Idec","/wiki/%C3%89lan","http://www.medpagetoday.com/ProductAlert/Prescriptions/tb/8522","#cite_ref-pmid17876741_39-0","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17876741","#cite_ref-40","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMc0706103","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18256405","#cite_ref-pmid18389881_41-0","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18389881","#cite_ref-Rice2005_42-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1212%2F01.WNL.0000158329.30470.D0","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15851719","#cite_ref-Tysabri_label_43-0","#cite_ref-Tysabri_label_43-1","#cite_ref-Tysabri_label_43-2","#cite_ref-Tysabri_label_43-3","#cite_ref-Tysabri_label_43-4","#cite_ref-Tysabri_label_43-5","http://tysabri.com/en_US/tysb/footer/TYSABRI-pi.pdf","/wiki/Wikipedia:Link_rot","#cite_ref-pmid18235044_44-0","http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=18235044","/wiki/Blood_(journal)","/wiki/Digital_object_identifier","http://dx.doi.org/10.1182%2Fblood-2007-10-120329","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18235044","#cite_ref-nejm-pml1_45-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa051782","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15947079","#cite_ref-nejm-pml2_46-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa051847","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15947078","#cite_ref-Van_Assche_47-0","#cite_ref-Van_Assche_47-1","http://content.nejm.org/cgi/content/full/353/4/362","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa051586","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/15947080","#cite_ref-Yousry_48-0","/wiki/Eugene_O._Major","http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1934511","/wiki/Digital_object_identifier","http://dx.doi.org/10.1056%2FNEJMoa054693","/wiki/PubMed_Central","//www.ncbi.nlm.nih.gov/pmc/articles/PMC1934511","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/16510746","#cite_ref-pmid17136224_49-0","#cite_ref-pmid17136224_49-1","/wiki/Digital_object_identifier","http://dx.doi.org/10.1358%2Fdot.2006.42.10.1042190","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17136224","#cite_ref-pmid17521672_50-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2Fj.jns.2006.04.011","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17521672","#cite_ref-pmid17122725_51-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1097%2F01.nrl.0000250948.04681.96","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17122725","#cite_ref-WSJ08_52-0","http://blogs.wsj.com/health/2008/08/01/brain-infections-return-for-multiple-sclerosis-drug-tysabri/?mod=googlenews_wsj","#cite_ref-pmid17434098_53-0","/wiki/Digital_object_identifier","http://dx.doi.org/10.1016%2FS1474-4422%2807%2970078-9","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/17434098","#cite_ref-NYT_54-0","#cite_ref-NYT_54-1","http://www.nytimes.com/2006/03/09/business/09drug.html?_r=1&scp=2&sq=natalizumab&st=nyt&oref=slogin","/wiki/The_New_York_Times","#cite_ref-55","http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4313b1-02-FDA-Errata.pdf","/wiki/Food_and_Drug_Administration","#cite_ref-56","/wiki/Digital_object_identifier","http://dx.doi.org/10.1097%2FMJT.0b013e31804bfa6a","/wiki/PubMed_Identifier","//www.ncbi.nlm.nih.gov/pubmed/18090880","#cite_ref-57","http://www.gazette.gc.ca/rp-pr/p2/2008/2008-04-16/pdf/g2-14208.pdf","/wiki/Canada_Gazette","/w/index.php?title=Natalizumab&action=edit&section=11","/w/index.php?title=Natalizumab&veaction=edit&section=11","http://www.tysabri.com/","http://www.elan.com/Products/united_states/tysabri_information_center.asp","http://www.biogenidec.com/site/019_2.html","/wiki/Template:Immunosuppressants","/wiki/Template_talk:Immunosuppressants","//en.wikipedia.org/w/index.php?title=Template:Immunosuppressants&action=edit","/wiki/Immunomodulator","/wiki/Immunosuppressive_drug","/wiki/Immunosuppressant","/wiki/ATC_code_L04","/wiki/Antimetabolite","/wiki/Purine_synthesis_inhibitor","/wiki/Azathioprine","/wiki/Mycophenolic_acid","/wiki/Pyrimidine_synthesis_inhibitor","/wiki/Leflunomide","/wiki/Teriflunomide","/wiki/Antifolate","/wiki/Methotrexate","/wiki/Macrolide","/wiki/Interleukin_2","/wiki/FKBP","/wiki/Cyclophilin","/wiki/Calcineurin","/wiki/Tacrolimus","/wiki/Ciclosporin","/wiki/Pimecrolimus","/wiki/Abetimus","/wiki/Gusperimus","/wiki/Thalidomide","/wiki/Lenalidomide","/wiki/Interleukin_1_receptor_antagonist","/wiki/Anakinra","/wiki/Mammalian_target_of_rapamycin","/wiki/Sirolimus","/wiki/Everolimus","/wiki/Ridaforolimus","/wiki/Temsirolimus","/wiki/Umirolimus","/wiki/Zotarolimus","/wiki/Antibody","/wiki/Monoclonal_antibodies","/wiki/Complement_component_5","/wiki/Eculizumab","/wiki/TNF_inhibitor","/wiki/Adalimumab","/wiki/Afelimomab","/wiki/Certolizumab_pegol","/wiki/Golimumab","/wiki/Infliximab","/wiki/Nerelimomab","/wiki/Interleukin_5","/wiki/Mepolizumab","/wiki/Immunoglobulin_E","/wiki/Omalizumab","/wiki/Interferon","/wiki/Faralimomab","/wiki/Interleukin_6","/wiki/Elsilimomab","/wiki/Interleukin_12","/wiki/Interleukin_23","/wiki/Lebrikizumab","/wiki/Ustekinumab","/wiki/CD3_(immunology)","/wiki/Muromonab-CD3","/wiki/Otelixizumab","/wiki/Teplizumab","/wiki/Visilizumab","/wiki/CD4","/wiki/Clenoliximab","/wiki/Keliximab","/wiki/Zanolimumab","/wiki/CD11a","/wiki/Efalizumab","/wiki/CD18","/wiki/Erlizumab","/wiki/CD20","/wiki/Afutuzumab","/wiki/Rituximab","/wiki/Ocrelizumab","/wiki/Pascolizumab","/wiki/CD23","/wiki/Gomiliximab","/wiki/Lumiliximab","/wiki/CD40_(protein)","/wiki/Teneliximab","/wiki/Toralizumab","/wiki/L-selectin","/wiki/Aselizumab","/wiki/CD80","/wiki/Galiximab","/wiki/Basigin","/wiki/Gavilimomab","/wiki/CD154","/wiki/Ruplizumab","/wiki/Belimumab","/wiki/CTLA-4","/wiki/Ipilimumab","/wiki/Tremelimumab","/wiki/Chloramphenicol_acetyltransferase","/wiki/Bertilimumab","/wiki/Lerdelimumab","/wiki/Metelimumab","/wiki/Integrin","/wiki/Interleukin-6_receptor","/wiki/Tocilizumab","/wiki/Lymphocyte_function-associated_antigen_1","/wiki/Odulimomab","/wiki/IL-2_receptor","/wiki/Basiliximab","/wiki/Daclizumab","/wiki/Inolimomab","/wiki/T_cell","/wiki/Zolimomab_aritox","/wiki/Atorolimumab","/wiki/Cedelizumab","/wiki/Fontolizumab","/wiki/Maslimomab","/wiki/Morolimumab","/wiki/Pexelizumab","/wiki/Reslizumab","/wiki/Rovelizumab","/wiki/Siplizumab","/wiki/Talizumab","/wiki/Telimomab_aritox","/wiki/Vapaliximab","/wiki/Vepalimomab","/wiki/Polyclonal_antibodies","/wiki/Anti-thymocyte_globulin","/wiki/Anti-lymphocyte_globulin","/wiki/Fusion_protein","/wiki/CTLA-4","/wiki/Abatacept","/wiki/Belatacept","/wiki/TNF_inhibitor","/wiki/Etanercept","/wiki/Pegsunercept","/wiki/Aflibercept","/wiki/Alefacept","/wiki/Rilonacept","/wiki/Template:Medicine_navs","/wiki/Lymphocyte","/wiki/Template:Lymphocytes","/wiki/Template:Lymphocytic_immune_system","/wiki/Template:Autoantigens","/wiki/Template:Autoantibodies","/wiki/Template:Complement_system","/wiki/Template:Immunoglobulin_superfamily_immune_receptors","/wiki/Template:Lymphoid_and_complement_immunodeficiency","/wiki/Template:Immunoproliferative_immunoglobulin_disorders","/wiki/Template:Hypersensitivity_and_autoimmune_diseases","/wiki/Template:Lymphoid_malignancy","/wiki/Template:Immunologic_techniques_and_tests","/wiki/Template:Immunostimulants","/wiki/Template:Immunosuppressants","/wiki/Template:Monoclonals_for_immune_system","/wiki/Template_talk:Monoclonals_for_immune_system","//en.wikipedia.org/w/index.php?title=Template:Monoclonals_for_immune_system&action=edit","/wiki/Monoclonal_antibodies","/wiki/Immune_system","/wiki/Immune_system","/wiki/Immunosuppression","/wiki/Adalimumab","/wiki/Anifrolumab","/wiki/Atorolimumab","/wiki/Belimumab","/wiki/Brodalumab","/wiki/Carlumab","/wiki/Dupilumab","/wiki/Eldelumab","/wiki/Fresolimumab","/wiki/Golimumab","/wiki/Lerdelimumab","/wiki/Lirilumab","/wiki/Mavrilimumab","/wiki/Metelimumab","/wiki/Morolimumab","/wiki/Namilumab","/wiki/Oxelumab","/wiki/Placulumab","/wiki/Sarilumab","/wiki/Sifalimumab","/wiki/Tabalumab","/wiki/Ipilimumab","/wiki/Tremelimumab","/wiki/Nivolumab","/wiki/Urelumab","/wiki/Bertilimumab","/wiki/Zanolimumab","/wiki/Afelimomab","/wiki/Elsilimomab","/wiki/Faralimomab","/wiki/Gavilimomab","/wiki/Inolimomab","/wiki/Maslimomab","/wiki/Nerelimomab","/wiki/Odulimomab","/wiki/Telimomab_aritox","/wiki/Vepalimomab","/wiki/Zolimomab_aritox","/wiki/Chimeric_antibody","/wiki/Basiliximab","/wiki/Clenoliximab","/wiki/Galiximab","/wiki/Gomiliximab","/wiki/Infliximab","/wiki/Keliximab","/wiki/Lumiliximab","/wiki/Priliximab","/wiki/Teneliximab","/wiki/Vapaliximab","/wiki/Humanized_antibody","/wiki/Aselizumab","/wiki/Apolizumab","/wiki/Benralizumab","/wiki/Cedelizumab","/wiki/Certolizumab_pegol","/wiki/Daclizumab","/wiki/Eculizumab","/wiki/Efalizumab","/wiki/Epratuzumab","/wiki/Erlizumab","/wiki/Etrolizumab","/wiki/Fontolizumab","/wiki/Itolizumab","/wiki/Lambrolizumab","/wiki/Lampalizumab","/wiki/Ligelizumab","/wiki/Mepolizumab","/wiki/Mogamulizumab","/wiki/Ocrelizumab","/wiki/Omalizumab","/wiki/Ozoralizumab","/wiki/Pascolizumab","/wiki/Pateclizumab","/wiki/Pexelizumab","/wiki/Pidilizumab","/wiki/PRO_140","/wiki/Reslizumab","/wiki/Rontalizumab","/wiki/Rovelizumab","/wiki/Ruplizumab","/wiki/Quilizumab","/wiki/Samalizumab","/wiki/Siplizumab","/wiki/Talizumab","/wiki/Teplizumab","/wiki/Tocilizumab","/wiki/Toralizumab","/wiki/Tregalizumab","/wiki/Vatelizumab","/wiki/Vedolizumab","/wiki/Visilizumab","/wiki/TGN1412","/wiki/Ibalizumab","/wiki/Otelixizumab","/wiki/Interleukin","/wiki/Briakinumab","/wiki/Canakinumab","/wiki/Fezakinumab","/wiki/Guselkumab","/wiki/Secukinumab","/wiki/Sirukumab","/wiki/Tralokinumab","/wiki/Ustekinumab","/wiki/Anrukinzumab","/wiki/Clazakizumab","/wiki/Enokizumab","/wiki/Gevokizumab","/wiki/Ixekizumab","/wiki/Lebrikizumab","/wiki/Olokizumab","/wiki/Perakizumab","/wiki/Tildrakizumab","/wiki/Lesion","/wiki/Besilesomab","/wiki/Technetium_(99mTc)_fanolesomab","/wiki/Lemalesomab","/wiki/Technetium_(99mTc)_sulesomab","/wiki/List_of_World_Health_Organization_Essential_Medicines","/wiki/List_of_withdrawn_drugs","/wiki/Clinical_trial","/wiki/Clinical_trial#Phase_III","/wiki/Clinical_trial#Phase_II","/wiki/Template:Medicine_navs","/wiki/Lymphocyte","/wiki/Template:Lymphocytes","/wiki/Template:Lymphocytic_immune_system","/wiki/Template:Autoantigens","/wiki/Template:Autoantibodies","/wiki/Template:Complement_system","/wiki/Template:Immunoglobulin_superfamily_immune_receptors","/wiki/Template:Lymphoid_and_complement_immunodeficiency","/wiki/Template:Immunoproliferative_immunoglobulin_disorders","/wiki/Template:Hypersensitivity_and_autoimmune_diseases","/wiki/Template:Lymphoid_malignancy","/wiki/Template:Immunologic_techniques_and_tests","/wiki/Template:Immunostimulants","/wiki/Template:Immunosuppressants","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","http://en.wikipedia.org/w/index.php?title=Natalizumab&oldid=564435207","/wiki/Help:Category","/wiki/Category:Monoclonal_antibodies","/wiki/Category:Immunosuppressants","/wiki/Category:Pages_using_citations_with_old-style_implicit_et_al.","/wiki/Category:All_articles_with_dead_external_links","/wiki/Category:Articles_with_dead_external_links_from_October_2010","/wiki/Category:Chemical_compounds_which_do_not_have_a_ChemSpiderID","/wiki/Category:Articles_with_changed_EBI_identifier","/wiki/Category:Drugboxes_which_contain_changes_to_verified_fields","/w/index.php?title=Special:UserLogin&returnto=Natalizumab&type=signup","/w/index.php?title=Special:UserLogin&returnto=Natalizumab","/wiki/Natalizumab","/wiki/Talk:Natalizumab","#","/wiki/Natalizumab","/w/index.php?title=Natalizumab&action=edit","/w/index.php?title=Natalizumab&veaction=edit","/w/index.php?title=Natalizumab&action=history","#","/w/index.php","//bits.wikimedia.org/static-1.22wmf12/skins/vector/images/search-ltr.png?303-4","/wiki/Main_Page","/wiki/Main_Page","/wiki/Portal:Contents","/wiki/Portal:Featured_content","/wiki/Portal:Current_events","/wiki/Special:Random","https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en","/wiki/Help:Contents","/wiki/Wikipedia:About","/wiki/Wikipedia:Community_portal","/wiki/Special:RecentChanges","//en.wikipedia.org/wiki/Wikipedia:Contact_us","/wiki/Special:WhatLinksHere/Natalizumab","/wiki/Special:RecentChangesLinked/Natalizumab","/wiki/Wikipedia:File_Upload_Wizard","/wiki/Special:SpecialPages","/w/index.php?title=Natalizumab&oldid=564435207","/w/index.php?title=Natalizumab&action=info","//www.wikidata.org/wiki/Q386119","/w/index.php?title=Special:Cite&page=Natalizumab&id=564435207","/w/index.php?title=Special:Book&bookcmd=book_creator&referer=Natalizumab","/w/index.php?title=Special:Book&bookcmd=render_article&arttitle=Natalizumab&oldid=564435207&writer=rl","/w/index.php?title=Natalizumab&printable=yes","//cs.wikipedia.org/wiki/Natalizumab","//de.wikipedia.org/wiki/Natalizumab","//es.wikipedia.org/wiki/Natalizumab","//fr.wikipedia.org/wiki/Natalizumab","//it.wikipedia.org/wiki/Natalizumab","//he.wikipedia.org/wiki/%D7%A0%D7%98%D7%9C%D7%99%D7%96%D7%95%D7%9E%D7%90%D7%91","//nl.wikipedia.org/wiki/Natalizumab","//ja.wikipedia.org/wiki/%E3%83%8A%E3%82%BF%E3%83%AA%E3%82%BA%E3%83%9E%E3%83%96","//pl.wikipedia.org/wiki/Natalizumab","//pt.wikipedia.org/wiki/Natalizumab","//ru.wikipedia.org/wiki/%D0%A2%D0%B8%D1%81%D0%B0%D0%B1%D1%80%D0%B8","//sr.wikipedia.org/wiki/Natalizumab","//sh.wikipedia.org/wiki/Natalizumab","#","//www.wikidata.org/wiki/Q386119#sitelinks-wikipedia","//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License","//creativecommons.org/licenses/by-sa/3.0/","//wikimediafoundation.org/wiki/Terms_of_Use","//wikimediafoundation.org/wiki/Privacy_policy","//www.wikimediafoundation.org/","//wikimediafoundation.org/wiki/Privacy_policy","/wiki/Wikipedia:About","/wiki/Wikipedia:General_disclaimer","//en.wikipedia.org/wiki/Wikipedia:Contact_us","//en.m.wikipedia.org/wiki/Natalizumab","//wikimediafoundation.org/","//bits.wikimedia.org/images/wikimedia-button.png","//www.mediawiki.org/","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/poweredby_mediawiki_88x31.png","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=scripts&skin=vector&*"],"instances":["medicine","united_states","anatomy","medical"],"pdf":["http://www.emea.europa.eu/pdfs/human/press/pr/67119009en.pdf","http://www.emea.europa.eu/pdfs/human/press/pr/15260806en.pdf","http://www.emea.europa.eu/humandocs/PDFs/EPAR/tysabri/H-603-PI-en.pdf","http://www.emea.europa.eu/humandocs/PDFs/EPAR/natalizumab/H-624-RAR-en.pdf","http://www.emea.europa.eu/pdfs/human/opinion/Natalizumab_Q&A_53096407en.pdf","http://emea.europa.eu/humandocs/PDFs/EPAR/tysabri/PR_Tysabri_13948908en.pdf","http://emea.europa.eu/humandocs/PDFs/EPAR/tysabri/Q&A_Tysabri_14590808en.pdf","http://www.fda.gov/medwatch/safety/2008/Tysabri_dhcp_letter.pdf","http://tysabri.com/en_US/tysb/footer/TYSABRI-pi.pdf","http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4313b1-02-FDA-Errata.pdf","http://www.gazette.gc.ca/rp-pr/p2/2008/2008-04-16/pdf/g2-14208.pdf"],"categories":["Monoclonal antibodies","Immunosuppressants"],"headings":["Indications","Adverse effects","Overdose","Physical and chemical properties","Pharmacokinetics","Mechanism of action","Interactions","Legal status","References","External links"],"image":["//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/b/bb/AntibodyChains.svg/200px-AntibodyChains.svg.png","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/magnify-clip.png","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","//bits.wikimedia.org/static-1.22wmf12/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[["food_and_drug_administration","united_states"],["remission","medicine"],["fatigue","medical"],["organ","anatomy"]],"members":["remission","food_and_drug_administration","organ","fatigue"],"related":["Integrin","Intravenous_infusion","Atomic_mass_unit","Humanized_antibody","Monoclonal_antibody","Cell_adhesion_molecule","Integrin","Multiple_sclerosis","Crohn's_disease","Biogen_Idec","Élan","Intravenous_therapy","Inflammation","Immune_system","Intestine","Blood–brain_barrier","Quality_of_life","Food_and_Drug_Administration_(United_States)","List_of_withdrawn_drugs","Progressive_multifocal_leukoencephalopathy","Interferon_beta-1a","Immunosuppressive_drug","European_Medicines_Agency","European_Union","Multiple_sclerosis","Crohn's_disease","Expanded_Disability_Status_Scale","Placebo","Interferon_beta-1a","Corticosteroid","Lesion","Antibody","Infusion","Monotherapy","Randomized_controlled_trial","Remission_(medicine)","Crohn's_disease","Tumor_necrosis_factor-alpha","Infliximab","Progressive_multifocal_leukoencephalopathy","JC_virus","Immunocompromised","Package_insert","Prevalence","Postmarketing_surveillance","Liver","Jaundice","Hepatotoxicity","Bilirubin","Elevated_transaminases","Challenge-dechallenge-rechallenge","Liver_function_tests","Sequela","Liver_transplantation","Death","Fatigue_(medical)","Allergy","Anaphylaxis","Headache","Nausea","Common_cold","Fever","Contraindication","Melanoma","Infection","Cancer","Humanized_antibody","Monoclonal_antibodies","Integrin","White_blood_cell","Organ_(anatomy)","Mechanism_of_action","Multiple_sclerosis_signs_and_symptoms","Lesion","Inflammation","T-lymphocyte","Blood–brain_barrier","Endothelium","Central_nervous_system","VLA-4","VCAM-1","Parenchyma","Osteopontin","Leukocyte","CD34","Addressin","Venules","Lymphatic_system","Peyer's_patches","Animal_model","Irritable_bowel_syndrome","Progressive_multifocal_leukoencephalopathy","Opportunistic_infection","JC_virus","Interferon_beta-1a","Sequela","Astrocytoma","Azathioprine","Corticosteroid","Infliximab","Contraindication","Immunosuppression","United_States_Food_and_Drug_Administration","Black_box_warning","Corticosteroid","Multiple_sclerosis","FDA_Fast_Track_Development_Program","Clinical_trial","First-line_treatment","Alosetron","Committee_for_Medicinal_Products_for_Human_Use","European_Medicines_Agency","Health_Canada","Prescription_drug","Physician"]}